BEST of ASCO Portugal 2024 - Localized Lung Cancer and Mesothelioma
BEST of ASCO Portugal 2024
Resumo
O tratamento do cancro de pulmão tem evoluído significativamente nos últimos anos principalmente devido ao desenvolvimento da imunoterapia e das terapêuticas alvo-molecular. À semelhança do que acontece na doença avançada, também na doença localizada têm-se verificado avanços importantes que se traduzem em alterações do paradigma de tratamento neste contexto de doença. Neste artigo é feita uma análise dos principais trabalhos apresentados no congresso anual da American Society of Clinical Oncology, 2024, no âmbito de cancro do pulmão localizado e mesotelioma.
Downloads
Referências
Rebecca L Siegel, Kimberly D Miller, Nikita Sandeep Wagle, Ahmedin Jemal. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17-48.
Megan E Daly, Navneet Singh, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022 Apr 20;40(12):1356-1384.
Scott J Antonia, Augusto Villegas, et al; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929.
Scott J Antonia, Augusto Villegas, et al; PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342-2350.
Peter Goldstraw, Kari Chansky, John Crowley, Ramon Rami-Porta, Hisao Asamura, Wilfried E E Eberhardt, Andrew G Nicholson, Patti Groome , Alan Mitchell, Vanessa Bolejack; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Jan;11(1):39-51.
Jean-Pierre Pignon, Hélène Tribodet, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul 20;26(21):3552-9.
NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014 May 3;383(9928):1561-71.
Antonio Nuccio, Giuseppe Viscardi, et al. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023 Dec:195:113404.
Tina Cascone, Mark M Awad, et al.; CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024 May 16;390(19):1756-1769.
Spicer JD, Gao S, Liberman M, et al. LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stge non-small-cell lung cancer (NSCLC). Ann Oncol 2023;34:Suppl 2:S1297-S1298 (https://www.annalsofoncology.org/article/S0923-7534(23)04196-0/fulltext).
Heymach JV, HarpoleD, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023;389:1672-84.
Lu S, Chang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial. JAMA 2024;331:201-11.
D. Yue, W. Wang, H. Liu, et al. VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC) (RATIONALE 315). Ann Oncol 2024;35:332-3 (https://www.annalsofoncology.org/article/S0923-7534(24)00012-7/fulltext).
Wen-Yu Zhai, Ze-Rui Zhao, Si Chen, et al. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis. J Immunother Cancer. 2022 Sep;10(9):e005160.
Jarushka Naidoo, Scott Antonia, et al. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. J Thorac Oncol. 2023 May;18(5):657-663.
Shun Lu , Terufumi Kato, Xiaorong Dong, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15;391(7):585-597.
Roy S. Herbst, Yi-Long Wu, Thomas John, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 Apr 1; 41(10): 1830–1840.
Jon Zugazagoitia, Luis Paz-Ares. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. J Clin Oncol. 2022 Feb 20;40(6):671-680.
Corinne Faivre-Finn , Michael Snee, et al.; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017 Aug;18(8):1116-1125.
Jeffrey Bogart, Xiaofei Wang, et al. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023 May 1;41(13):2394-2402.
Luis Paz-Ares, Mikhail Dvorkin, et al.; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939.
Horn L, Mansfield AS, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220.
Paul Baas, Arnaud Scherpereel, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 Jan 30;397(10272):375-386.
Quincy Chu, Francesco Perrone, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023 Dec 16;402(10419):2295-2306.
Gérard Zalcman, Julien Mazieres, et al.; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-1414.
Ryota Tamura, Toshihide Tanaka, et al. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol. 2019 Nov 11;37(1):2.
